Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Helen Jin

Nephrology Port Washington, NY Medical Doctor

NPI 1306818554 CMS profile 655559

50 Seaview Blvd, Port Washington, NY 11050

Open in the dashboard

General payments

$540

27 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Helen Jin of Port Washington, NY is reported in the CMS Open Payments database as having received $540 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 2
2024 General $241 12
2023 General $266 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Helen Jin
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Helen Jin were reported at $33. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Helen Jin Nephrology median Middle half National median
2019 $0 $236 $90–$588 $163
2020 $0 $135 $46–$364 $114
2021 $0 $202 $67–$551 $132
2022 $0 $242 $77–$695 $149
2023 $266 $254 $84–$766 $160
2024 $241 $300 $99–$852 $164
2025 $33 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. ViiV Healthcare Company $265 12 payments
  2. Gilead Sciences, Inc. $198 10 payments
  3. Phathom Pharmaceuticals, Inc. $57 4 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $540 27 payments
Products named General payments · program years 2023–2025
  1. CABENUVA $213 10 payments
  2. DOVATO $51 2 payments
  3. VOQUEZNA Gastroenterology $42 3 payments
  4. XIFAXAN $21 1 payment
  5. VOQUEZNA Gastroenterology $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

447

Median for Internal Medicine: 777

Drug cost

$26,462

Median for Internal Medicine: $73,373

Branded share of claims

9.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vascepa Icosapent Ethyl Brand 15 $12,093
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $10,205
Metformin Hcl Generic 47 $638
Albuterol Sulfate Hfa Albuterol Sulfate Brand 13 $544
Atorvastatin Calcium Generic 62 $527
Losartan Potassium Generic 45 $484
Triamcinolone Acetonide Generic 19 $334
Rosuvastatin Calcium Generic 17 $270
Metoprolol Succinate Generic 21 $243
Amlodipine Besylate Generic 42 $203

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$8,121

Medicare's payments for the services billed

Medicare patients

63

Average age 74

Services billed

106

34 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Arthritis 35%
Chronic kidney disease 21%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CABENUVA
  • ViiV Healthcare Company $157
$157 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $42
$42 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $21
$21 — —
DOVATO
  • ViiV Healthcare Company $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record